These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8862724)

  • 1. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
    Hasinoff BB; Yalowich JC; Ling Y; Buss JL
    Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
    Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
    Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
    Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
    Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells.
    Malisza KL; Hasinoff BB
    Free Radic Biol Med; 1996; 20(7):905-14. PubMed ID: 8743977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
    Langer SW; Sehested M; Jensen PB
    Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
    Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
    Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
    Hasinoff BB; Creighton AM; Kozlowska H; Thampatty P; Allan WP; Yalowich JC
    Mol Pharmacol; 1997 Nov; 52(5):839-45. PubMed ID: 9351975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
    Hasinoff BB; Wu X; Yang Y
    J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
    Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
    Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane (ICRF-187).
    Weiss G; Loyevsky M; Gordeuk VR
    Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
    Sargent JM; Williamson CJ; Yardley C; Taylor CG; Hellmann K
    Br J Cancer; 2001 Apr; 84(7):959-64. PubMed ID: 11286477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.